The immunotherapy of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 3, Issue 4, 2000, Pages 303-307

  Dalgleish, A G ^a   Perry, M J A ^a   Eaton, J D ^a   Hrouda, D ^a   Todryk, S M ^a   Kirby, R S ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer vaccines; HSVtk and gene therapy; Immunotherapy; Prostate cancer

Indexed keywords

CANCER VACCINE; THYMIDINE KINASE; TUMOR ANTIGEN;

ADVANCED CANCER; ARTICLE; CANCER IMMUNOTHERAPY; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; TUMOR GROWTH;

EID: 0034507931     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500487     Document Type: Article

References (49)

1. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
2. Prostate biopsy after definitive treatment by interstitial 125iodine implant or external beam radiation therapy
3. Carcinoma of the prostate: Results of post-irradiation biopsy
4. Leuprolide with and without flutamide in advanced prostate cancer
5. Gene therapy for prostate cancer
6. The role of immunotherapy for urological tumours
7. Immunological surveillance for cancer therapy in neoplasia
8. Occult carcinoma of the prostate: An oversight of immune surveillance - A working hypothesis
9. Granulomatous prostatitis. A mimic of carcinoma of the prostate
10. The lymphatic drainage of the rat prostate and its status as an immunologically privileged site
11. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma
12. Immune evaluation with skin testing. A study of testicular, prostatic, and bladder neoplasms
13. Impaired eytokine production in whole blood cell cultures of patients with urological carcinomas
14. Immunotherapy of advanced prostate cancer: A phase I/II trial using Mycobacterium vaccae (SRL172)
15. Molecular characterization of defective antigen processing in human prostate cancer
16. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy
17. Immunobiology and immunotherapy of melanoma
18. Preventing abnormalities in signal transduction of T cells in cancer: The promise of cytokine gene therapy
19. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
20. Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer
21. Mycobacterium vaccae (SRL172): A potential immunological adjuvant evaluated in rat prostate cancer
22. Comparison of IL-2- and IL-4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumour vaccine
23. Allogeneic whole tumour cell vaccination in the rat model of prostate cancer
24. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
25. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens
26. PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus
27. The development of therapeutic vaccines of the management of malignant melanoma
28. Expression of the prostate-specific membrane antigen
29. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells
30. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
31. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity
32. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49
33. A novel prostate carcinoma-associated glycoprotein complex (PAC) recognized by monoclonal antibody TURP-27
34. Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicator
35. Active specific immnotherapy: PEM as a potential target molecule
36. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas
37. Characterization of a prostate carcinoma mucin-like antigen (PMA)
38. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
39. Ras gene mutations in human prostate cancer
40. Activated ras alleles in human carcinoma of the prostate are rare
41. Infrequent RAS oncogene mutations in human prostate cancer
42. Genetic alterations in prostate cancer
43. p53 oncogene mutations in human prostate cancer specimens
44. p53 in prostate cancer: Frequent expressed transition mutations
45. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer
46. p53 oncogene mutations in three human prostate cancer cell lines
47. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes
48. Paracrine cytokine adjuvants in cancer immunotherapy
49. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology